Molsidomin Stada (Molsidomine)

Molsidomine is a prodrug that is converted in the liver to a nitric oxide‑releasing compound. The released nitric oxide activates guanylate cyclase in vascular smooth muscle, increasing cyclic GMP levels, which leads to relaxation of the vessels, vasodilation, and reduced cardiac workload.

The dosage of Molsidomin is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerance. The prescriber determines the appropriate strength, frequency, and duration of therapy according to current medical guidelines.

Safety data for molsidomine during pregnancy and lactation are limited. It is generally classified as a drug with unknown pregnancy category, and use is only recommended if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Molsidomin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Molsidomin belongs to the nitric oxide donor class, offering vasodilation without the rapid tolerance seen with organic nitrates. Compared with traditional nitrates, it provides a more sustained effect and may be combined with other antianginal agents, though concurrent use with nitrates is generally avoided due to additive hypotensive risk.

Molsidomin tablets should be stored at room temperature, below 25 °C, in their original packaging. Protect them from moisture, direct sunlight, and extreme temperatures. Keep the container tightly closed and out of reach of children.

Molsidomin is taken orally as a tablet. The patient should swallow the tablet whole with a glass of water, preferably at the same times each day as directed by the prescriber. It may be taken with or without food, unless otherwise instructed.

The most serious risks include severe hypotension, syncope (fainting), and rare allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience a sudden drop in blood pressure, loss of consciousness, or signs of a severe allergic response.

Molsidomin should be avoided in patients with known hypersensitivity to molsidomine or any component of the formulation, those taking concomitant nitrates, and individuals with severe hypotension or uncontrolled cardiovascular instability. Caution is also advised for patients with significant hepatic or renal impairment.